ResMed (RMD) Tops Q4 EPS by 2c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BofA/Merrill Lynch Downgrades ResMed (RMD) to Neutral
August 2, 2017 6:35 AM EDTBofA/Merrill Lynch downgraded ResMed (NYSE: RMD) from Buy to Neutral.
Analyst William Dunlop says FY 2018 should be "great" but does not believes the current trajectory is setting to make it so. The analyst comments that market share gains appear... More
